Aptorum’s Shares Jump 115% on Proposed DiamiR Merger
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) is a London-based pharmaceutical company founded in 2010 by Ian Huen. The firm focuses on discovering and commercializing novel therapeutics to address unmet medical needs across orphan diseases, infectious diseases, metabolic disorders, and women’s health. As of August 21, 2025, APM shares closed at USD 2.74, reflecting a 115.75 percent increase from the previous trading period, with a total trading volume of 23.9 million shares on the Nasdaq.
Corporate Structure and Operations
Aptorum Group employs between 11 and 50 staff at its London headquarters. The company utilizes a multidisciplinary team of specialists in biotechnology research, pharmaceutical development, life sciences, and therapeutics. As a public entity, Aptorum maintains corporate offices to support research and development (R&D), clinical operations, and investor relations in compliance with U.S. and European securities regulations.
Pharmaceutical Merger by Michał Parzuchowski
Developments and News
- Form 6-K Filing (July 22, 2025): Aptorum announced a proposed merger with DiamiR Biosciences Corp. This merger includes a management services agreement under which Aptorum Therapeutics will compensate DiamiR for services related to diagnostics, as well as an intellectual property licensing arrangement. Following the merger, DiamiR shareholders are expected to own approximately 70 percent of the combined entity. Aptorum also plans to change its corporate status to a Delaware corporation.
- Schedule 13G/A Amendment (May 15, 2025): L1 Capital Global Opportunities Master Fund, Ltd. reported no beneficial ownership of Aptorum’s Class A ordinary shares as of March 31, 2025.
- Form 20-F Filing (April 30, 2025): Aptorum submitted its annual report for the fiscal year ending December 31, 2024, as required by SEC regulations for foreign private issuers.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Market Capitalization | USD 9.07 million |
| Enterprise Value | USD 11.55 million |
| 52-Week Share Price Range | USD 0.46 – 7.49 |
| Total Cash (most recent quarter) | USD 874,240 |
| Total Debt/Equity (most recent quarter) | 28.49 percent |
| Net Income (trailing twelve months) | –USD 4.27 million |
| Diluted EPS (trailing twelve months) | –0.78 |
| Levered Free Cash Flow (trailing twelve months) | –USD 1.96 million |
| Return on Assets (trailing twelve months) | –8.33 percent |
| Return on Equity (trailing twelve months) | –30.62 percent |
Aptorum’s balance sheet indicates modest cash reserves relative to its debt levels. Negative net income and negative free cash flow suggest continued investment in research and development, with the merger with DiamiR aimed at enhancing its molecular diagnostic capabilities.
Market Position and Industry Context
Operating in the biotechnology research and healthcare sector, Aptorum is classified as a small-cap, early-stage player. It focuses on developing first-in-class or best-in-class innovations, which situates it among peers targeting orphan and specialty disease markets. The planned integration of DiamiR’s molecular diagnostics aligns with industry trends toward earlier disease detection, particularly in neurodegeneration and oncology. Regulatory pathways and market acceptance remain significant considerations for the combined entity.
tl;dr
On July 22, 2025, Aptorum Group filed a Form 6-K disclosing a proposed merger with DiamiR Biosciences, detailing service agreements, intellectual property licensing, and a 70/30 share-ownership structure following the merger. As of August 21, 2025, shares traded at USD 2.74 (+115.75 percent). The company holds USD 874,000 in cash against a 28.49 percent debt-to-equity ratio and reported a USD 4.27 million net loss over the trailing twelve months. The completion of the merger and the integration of diagnostic offerings represent critical next steps for the organization.